Vinblastine-induced posterior reversible encephalopathy syndrome

J Oncol Pharm Pract. 2019 Dec;25(8):2019-2022. doi: 10.1177/1078155218816776. Epub 2018 Dec 11.

Abstract

Posterior reversible encephalopathy syndrome has recently been recognized as an entity characterized by central neurological and radiological manifestations. There are increasing reports of posterior reversible encephalopathy syndrome associated with the use of chemotherapeutic agents. We herein present a case of posterior reversible encephalopathy syndrome occurring in a patient with Hodgkin's lymphoma after taking two courses of adriamycin, bleomycin, vinblastine, dacarbazine chemotherapy. A prompt recognition of posterior reversible encephalopathy syndrome associated with vinblastine and discontinuation of this drug is paramount to prevent severe neurological damage.

Keywords: Hodgkin's lymphoma; Vinblastine; posterior reversible encephalopathy syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bleomycin / administration & dosage
  • Dacarbazine / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Hodgkin Disease / drug therapy
  • Humans
  • Posterior Leukoencephalopathy Syndrome / chemically induced*
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects*

Substances

  • Bleomycin
  • Vinblastine
  • Dacarbazine
  • Doxorubicin